Will the U.S. Create Barriers to LDCs’ Future Access to Medicines?

Earlier this year, WTO Least Developed Country Members requested an unconditional extension of the expiring WTO TRIPS transition period that exempts them from having to implement pharmaceutical patents and other intellectual property protections that constrain their ability to make or procure low-cost generic medicines. Informed sources indicate that the U.S. is currently opposing the LDC [...]